PrJSC “Pharmaceutical Firm “Darnitsa” will establish a representative office in Uzbekistan, the company reported in the information disclosure system of the National Securities and Stock Market Commission (NSSMC).
It is specified that, according to the decision of the Supervisory Board of Darnitsa adopted on July 12, the representative office will be established “in connection with the constant development”.
As reported, in 2023, Darnitsa increased its share of exports to 4%. The company exports its products to 17 countries. In particular, thanks to the confirmation of the stability of medicines in the southern climate zone and compliance in Australia, the company can expand cooperation with New Zealand, Malaysia, Yemen and South Africa. At the same time, in 2016, Darnitsa stopped exporting to the Russian Federation, and after February 24, 2022, to Belarus.
In June 2023, Darnitsa registered one of its medicines in Australia, which, according to the company, is known for some of the strictest regulatory rules in the world.
In 2023, the company increased its net income from operating activities by 32.8% compared to 2022 to UAH 6.969 billion. The company named new products and higher selling prices as the main factors of the increase in revenue.
“Darnitsa” is the leader of the Ukrainian pharmaceutical market in physical terms. The company has been present on the market for over 90 years and produces medicines of 180 brands in 15 different forms. The strategic areas of development of the portfolio are cardiology, neurology, and pain management. According to the Unified State Register of Legal Entities and Individual Entrepreneurs, the ultimate beneficiary of the company is Hlib Zagoriy.
